CA2328730C - Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein - Google Patents

Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein Download PDF

Info

Publication number
CA2328730C
CA2328730C CA002328730A CA2328730A CA2328730C CA 2328730 C CA2328730 C CA 2328730C CA 002328730 A CA002328730 A CA 002328730A CA 2328730 A CA2328730 A CA 2328730A CA 2328730 C CA2328730 C CA 2328730C
Authority
CA
Canada
Prior art keywords
vitamin
nsaid
group
hypertension
supplement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002328730A
Other languages
English (en)
French (fr)
Other versions
CA2328730A1 (en
Inventor
Krishnamurti Dakshinamurti
Rajat Sethi
Naranjan S. Dhalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Medicure Inc
Original Assignee
University of Manitoba
Medicure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba, Medicure Inc filed Critical University of Manitoba
Publication of CA2328730A1 publication Critical patent/CA2328730A1/en
Application granted granted Critical
Publication of CA2328730C publication Critical patent/CA2328730C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002328730A 1998-04-16 1999-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein Expired - Fee Related CA2328730C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/061,173 1998-04-16
US09/061,173 US6051587A (en) 1998-04-16 1998-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
PCT/CA1999/000331 WO1999053928A1 (en) 1998-04-16 1999-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein

Publications (2)

Publication Number Publication Date
CA2328730A1 CA2328730A1 (en) 1999-10-28
CA2328730C true CA2328730C (en) 2007-08-21

Family

ID=22034118

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002328730A Expired - Fee Related CA2328730C (en) 1998-04-16 1999-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein

Country Status (12)

Country Link
US (1) US6051587A (https=)
EP (1) EP1071430B1 (https=)
JP (1) JP2002512194A (https=)
AT (1) ATE319457T1 (https=)
AU (1) AU765749B2 (https=)
BR (1) BR9909672A (https=)
CA (1) CA2328730C (https=)
DE (1) DE69930243T2 (https=)
ES (1) ES2260906T3 (https=)
IL (1) IL139681A0 (https=)
NZ (1) NZ508142A (https=)
WO (1) WO1999053928A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6339085B1 (en) 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
EP1872797A3 (en) 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
EP1531157B1 (en) * 2000-02-29 2008-03-19 Medicure International Inc. Cardioprotective phosphonates
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU3718501A (en) 2000-02-29 2001-09-12 Medicure Int Inc Cardioprotective phosphonates and malonates
WO2001072309A2 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
WO2002039994A2 (en) 2000-11-20 2002-05-23 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
EP2392562B1 (en) 2002-07-29 2018-03-07 Cardax Pharma, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2004084910A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
EP1610783A2 (en) * 2003-03-27 2006-01-04 Medicure Inc. Modulation of cell death
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US20060019929A1 (en) * 2004-07-07 2006-01-26 Albert Friesen Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
CA2575849A1 (en) * 2004-08-10 2006-02-16 Medicure International Inc. Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
WO2006050598A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
EP1827455A1 (en) * 2004-11-26 2007-09-05 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
JP2008526783A (ja) * 2005-01-05 2008-07-24 メディキュア・インターナショナル・インコーポレーテッド トリグリセリドレベルを調節するための化合物及び方法
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
DOP2007000055A (es) 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
MX2008003230A (es) * 2008-03-07 2009-09-07 Senosiain S A De C V Lab Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
WO2014063134A1 (en) * 2012-10-19 2014-04-24 New York University Methods for inhibiting osteolysis
RU2629367C1 (ru) * 2016-11-02 2017-08-29 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Нестероидное противовоспалительное средство на основе напроксена, обладающее низкой гастротоксичностью

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4492M (https=) * 1965-07-07 1966-10-10
FR6707M (https=) * 1966-04-29 1969-02-17
FR6723M (https=) * 1966-12-30 1969-02-17
FR7503M (https=) * 1967-05-30 1969-12-08
GB1236531A (en) * 1969-02-12 1971-06-23 Soc D Etudes Prod Chimique Adenin derivative
JPS53121765A (en) * 1977-04-01 1978-10-24 Chugai Pharmaceut Co Ltd Pyridoxal derivatives
IL62602A (en) * 1980-05-19 1984-06-29 Labaz Sanofi Nv Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them
US4542026A (en) * 1983-04-29 1985-09-17 Jose Rios Method of treating vasomotor disorders
US4564614A (en) * 1984-10-11 1986-01-14 Pfizer Inc. Antiinflammatory methods
FR2641189B1 (fr) * 1988-06-20 1991-05-10 Timol Mamoojee Compositions pharmaceutiques contenant de l'acide acetyl salicylique et de la vitamine b6
US20040180865A1 (en) * 1993-06-04 2004-09-16 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease

Also Published As

Publication number Publication date
EP1071430A1 (en) 2001-01-31
AU765749B2 (en) 2003-09-25
WO1999053928A1 (en) 1999-10-28
DE69930243D1 (de) 2006-05-04
CA2328730A1 (en) 1999-10-28
NZ508142A (en) 2002-11-26
BR9909672A (pt) 2007-07-31
ES2260906T3 (es) 2006-11-01
AU3402999A (en) 1999-11-08
JP2002512194A (ja) 2002-04-23
US6051587A (en) 2000-04-18
IL139681A0 (en) 2002-02-10
ATE319457T1 (de) 2006-03-15
EP1071430B1 (en) 2006-03-08
DE69930243T2 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
CA2328730C (en) Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
CN100348189C (zh) DPP－IV抑制剂与PPAR－α化合物的组合
CA2260943C (en) Formulation of 5-ht agonists
KR20080024511A (ko) 심혈관 이벤트 발병 예방용 조성물
JP2004531468A5 (https=)
US20100048518A1 (en) Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent
NO322314B1 (no) Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament.
KR20000070733A (ko) 위장 리파아제 억제제의 용도
US4564614A (en) Antiinflammatory methods
WO2000043017A1 (en) Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
JP4786127B2 (ja) 色素沈着改善治療薬
AU666992B2 (en) Pharmaceutical composition for preventing or treating arteriosclerosis
Trombelli et al. Effect of pretreatment with ketorolac tromethamine on post‐operative pain following periodontal surgery
CA2294095C (en) Synergistically acting compositions for selectively combating tumor tissue
WO2002036127A2 (en) Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
CA2100777C (en) Pharmaceutical composition containing granisetron and dexamethasone
KR20070086007A (ko) 당뇨병의 치료를 위한 의약 조성물
US4663345A (en) Etodolac for treatment of gout
US5962020A (en) Composition and method for preventing and/or treating microalbuminuria
US4742076A (en) Etodolac for lowering rheumatoid factor
EP2482658B1 (en) Methods and compositions for treatment of raynaud&#39;s phenomenon
US3298916A (en) Treatment and composition for high blood pressure and palpitation
JPH04112823A (ja) 痴呆治療剤
JP2006193511A (ja) 糖尿病の治療のための医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed